Nimotop (Nimodipine)

Nimodipine, the active ingredient in Nimotop, is a calcium channel blocker presented as an oral tablet for oral use. It is employed to prevent cerebral vasospasm following subarachnoid hemorrhage in patients at risk of delayed ischemic neurological deficits.

GNH USA supplies Nimotop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nimotop is a calcium channel blocker used in the management of cerebrovascular complications after hemorrhagic events.

- Subarachnoid hemorrhage: reduces the incidence of delayed cerebral vasospasm and associated ischemia. - Aneurysmal SAH recovery: supports neurological outcome by maintaining cerebral blood flow. - Neurosurgical procedures: provides prophylaxis against procedure‑related cerebral vasospasm.

Nimotop may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Hypotension: transient drop in blood pressure, especially when standing. - Nausea or vomiting: gastrointestinal discomfort. - Flushing or warmth: sensation of heat on the skin. - Dizziness or light‑headedness: related to blood pressure changes. - Tachycardia: increased heart rate in some patients.

Serious or Rare Side Effects: - Severe hypotension: may require medical intervention. - Myocardial infarction: rare but reported in vulnerable patients. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Allergic reaction: rash, pruritus, or anaphylaxis.

Before initiating Nimotop, clinicians should evaluate patient‑specific risk factors and monitor for potential complications.

- Renal impairment: monitor renal function and adjust therapy as needed. - Hepatic impairment: use with caution; assess liver enzymes regularly. - Hypotension: check blood pressure before and during treatment. - Concomitant vasodilators: increased risk of additive blood pressure lowering. - Pregnancy: safety not established; avoid unless benefit outweighs risk. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Nimodipine can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise plasma nimodipine levels. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect. - Other calcium channel blockers: additive vasodilatory effect leading to profound hypotension.

Moderate Interactions (Monitor Closely): - Beta‑blockers: potential for enhanced bradycardia. - Diuretics: may potentiate hypotensive response. - Antihypertensive agents: require close blood pressure monitoring.